Romosozumab
Romosozumab (Anti-Sclerostin Antibody)
A monoclonal antibody that inhibits sclerostin, a negative regulator of bone formation. FDA-approved (Evenity) for severe osteoporosis with a dual anabolic and anti-resorptive mechanism.
Mechanism of Action
Romosozumab binds and inhibits sclerostin, releasing the Wnt signaling pathway in osteoblasts. This simultaneously increases bone formation and decreases bone resorption — a unique dual mechanism.
Health Claims & Evidence
Dual anabolic and anti-resorptive bone effects
Rapid and significant bone density increases
Reduces fracture risk
Short-Term Effects
Rapid bone density increases within months.
Long-Term Effects
Significant bone density gains over 12-month course.
Side Effects
Injection site reactions, arthralgia. Black box warning: increased risk of MI and stroke.
Contraindications
Recent MI or stroke. Cardiovascular risk assessment required.
This profile is provided for educational research only. It is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Verify primary sources and consult a qualified healthcare professional for medical decisions.
Research Papers
Romosozumab in postmenopausal osteoporosis
Cosman et al. · New England Journal of Medicine · 2016
Educational research only. This profile is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Consult a qualified healthcare professional for medical decisions.
Related Peptides
Explore the research further
Our AI Research Advisor can help you explore the evidence on Romosozumab and related peptides, and prepare an educational research summary.
Explore Research